drugset / Trial / NCT06369155
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Phase 2
Recruiting
25 enrolled
Joyce Liu, MD
National Cancer Institute (NCI) · collabZentalis · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Timeline
- Start
- 2025-03-05
- Primary completion
- 2027-01-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | 25 mg | Oral |
| Subject | Azenosertib | Small molecule | 100 mg | Oral |